Suven Pharmaceuticals バランスシートの健全性

財務の健全性基準チェック /66

Suven Pharmaceuticalsの総株主資本は₹20.5B 、総負債は₹650.0Mで、負債比率は3.2%となります。総資産と総負債はそれぞれ₹22.5Bと₹2.0Bです。 Suven Pharmaceuticalsの EBIT は₹2.7Bで、利息カバレッジ比率51.4です。現金および短期投資は₹8.2Bです。

主要情報

3.2%

負債資本比率

₹649.96m

負債

インタレスト・カバレッジ・レシオ	51.4x
現金	₹8.21b
エクイティ	₹20.51b
負債合計	₹2.03b
総資産	₹22.54b

財務の健全性に関する最新情報

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08

Recent updates

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Aug 03

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Mar 26

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Mar 07

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Sep 03

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Apr 13

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Feb 08

財務状況分析

短期負債: SUVENPHARの短期資産 ( ₹12.6B ) が短期負債 ( ₹1.1B ) を超えています。

長期負債: SUVENPHARの短期資産 ( ₹12.6B ) が長期負債 ( ₹965.3M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: SUVENPHAR総負債よりも多くの現金を保有しています。

負債の削減: SUVENPHARの負債対資本比率は、過去 5 年間で16.6%から3.2%に減少しました。

債務返済能力: SUVENPHARの負債は営業キャッシュフローによって十分にカバーされています ( 551.5% )。

インタレストカバレッジ: SUVENPHARの負債に対する利息支払いは EBIT ( 51.4 x coverage) によって十分にカバーされています。

Suven Pharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Recent updates

Suven Pharmaceuticals Limited Announces the Resignation of Brian Shaughnessy as Chief Commercial Officer and Senior Management Personnel

Suven Pharmaceuticals Limited Announces Board Changes

Suven Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes

Suven Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 09, 2024

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 09, 2024

Investor sentiment improves as stock rises 18%

Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) agreed to acquire 67.50% stake in Sapala Organics Private Limited for INR 2.3 billion.

Full year 2024 earnings released: EPS: ₹11.80 (vs ₹16.16 in FY 2023)

Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) agreed to acquire Cohance Lifesciences Limited.

Consensus revenue estimates fall by 14%

Price target increased by 17% to ₹710

Third quarter 2024 earnings released: EPS: ₹1.84 (vs ₹4.23 in 3Q 2023)

Suven Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Suven Pharmaceuticals Limited Announces CFO Changes

Suven Pharmaceuticals Limited Announces CFO Changes

Suven Pharmaceuticals Limited Appoints Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju as Managing Director

Suven Pharmaceuticals Limited Approves Interim Dividend for the Financial Year 2023-24

Suven Pharmaceuticals Limited Proposes Interim Dividend for the Financial Year 2022-23

Second quarter 2024 earnings released: EPS: ₹3.13 (vs ₹2.83 in 2Q 2023)

Suven Pharmaceuticals Limited, Annual General Meeting, Dec 15, 2023

Suven Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 09, 2023

First quarter 2024 earnings released: EPS: ₹4.74 (vs ₹4.22 in 1Q 2023)

Suven Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Insider recently sold ₹3.4m worth of stock

Third quarter 2023 earnings released: EPS: ₹4.23 (vs ₹6.29 in 3Q 2022)

Advent International Corporation agreed to acquire 50.1% stake in Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) from Jasti Family for INR63 billion.

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

High number of new directors

Second quarter 2023 earnings released: EPS: ₹2.83 (vs ₹3.81 in 2Q 2022)

Blackstone, Advent Reportedly to Buy Stake in Suven Pharma

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Full year 2022 earnings: EPS exceeds analyst expectations

Suven Pharmaceuticals Limited to Report Q4, 2023 Results on May 15, 2023

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS exceeds analyst expectations

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 18, 2022

Suven Pharmaceuticals Limited to Report Q4, 2022 Results on May 09, 2022

High number of new and inexperienced directors

Suven Pharmaceuticals Limited (BSE:543064) agreed to acquire Casper Pharma Private Limited for approximately $20 million.

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Investor sentiment improved over the past week

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Suven Pharmaceuticals to Evaluate the Acquisition Opportunity of Casper Pharma

Suven Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 08, 2022

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Second quarter 2022 earnings released: EPS ₹3.81 (vs ₹2.91 in 2Q 2021)

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Full year 2021 earnings released: EPS ₹14.23 (vs ₹12.45 in FY 2020)

Upcoming dividend of ₹1.00 per share

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Price target increased to ₹572

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Full year 2021 earnings released: EPS ₹14.23 (vs ₹12.45 in FY 2020)

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

New 90-day high: ₹507

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Suven Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 10, 2021

Blackstone, CVC & Warburg Reportedly in Race to Buy Suven Pharma

New 90-day high: ₹503

Investor sentiment improved over the past week

New 90-day high: ₹444

New 90-day high: ₹407

Market bids up stock over the past week

Second quarter 2021 earnings released: EPS ₹2.91

New 90-day low: ₹314

財務の健全性基準チェック /66